RCEL Stock Forecast: AVITA Medical, Inc. Price Predictions for 2026-2027
The 3 Wall Street analysts covering AVITA Medical, Inc. hold a median 12-month price target of $20 — +29.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 85 of 100 as at 21 Nov 2026 — inside the top quartile. Here, the model and the Street point the same way.
One number for the whole business
Consensus tells you what everyone already believes. The model scores AVITA Medical, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (98): The shares have been drifting up relative to others.
Issuance (23): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
RCEL stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on RCEL, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +29.4% from it.
Of the 20 most recent actions, 8 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 12 Nov 2026 | TD Cowen | Maintains | Buy | $20 → $22 |
| 7 Nov 2026 | Lake Street | Maintains | Buy | — |
| 6 Nov 2026 | BTIG | Maintains | Buy | $15 → $21 |
| 6 Nov 2026 | Lake Street | Maintains | Buy | $12 → $20 |
| 12 Oct 2026 | BTIG | Maintains | Buy | $11 → $15 |
| 28 Aug 2026 | Lake Street | Maintains | Buy | $8.00 → $12 |
| 19 Aug 2026 | BTIG | Maintains | Buy | $7.00 → $11 |
| 19 Aug 2026 | TD Cowen | Maintains | Buy | $12 → $14 |
| 7 Aug 2026 | BTIG | Upgrade | Buy | $7.00 |
| 15 May 2026 | Lake Street | Upgrade | Buy | $3.50 → $6.00 |
| 9 Apr 2026 | D. Boral Capital | Maintains | Buy | — |
| 8 Apr 2026 | D. Boral Capital | Maintains | Buy | — |
| 5 Mar 2026 | Northland Capital Markets | Initiates | Outperform | — |
| 17 Feb 2026 | D. Boral Capital | Maintains | Buy | — |
| 26 Jan 2026 | D. Boral Capital | Maintains | Buy | — |
| 16 Jan 2026 | Lake Street | Maintains | Hold | — |
| 15 Jan 2026 | D. Boral Capital | Maintains | Buy | — |
| 20 Nov 2025 | BTIG | Upgrade | Neutral | — |
| 7 Nov 2025 | D. Boral Capital | Maintains | Buy | — |
| 17 Oct 2025 | D. Boral Capital | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for RCEL.
This page is one stock. Monday covers all of them.
RCEL appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
RCEL vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, AVITA Medical, Inc. returned +306.8% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
RCEL analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 5.8×
- Price / book
- —
- EV / EBITDA
- —
Cheaper than 18% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- 81.9%
- Operating margin
- −33.9%
- Net margin
- —
Higher than 92% of US stocks
Higher than 20% of US stocks
- Return on equity
- —
- Return on assets
- −32.5%
- Dividend yield
- —
Higher than 13% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
AVITA Medical, Inc. has a market value of $495.0M and an enterprise value of $527.4M.
Revenue in the twelve months to 30 June 2026: $75.6M. The latest quarter grew 17.8% year on year.
Net income over the same four quarters: −$43.1M, a −57.0% net margin.
Diluted earnings per share, trailing twelve months: −$1.44.
Free cash flow in the twelve months to 30 June 2026: −$25.3M.
AVITA Medical, Inc. employs 226 people — $335K of revenue per employee.
Data provided by Twelve Data
RCEL and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at RCEL’s peer groups, ranked by the model: healthcare stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own AVITA Medical, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about RCEL
What is the RCEL stock price forecast for 2026-2027?
The 3 Wall Street analysts covering AVITA Medical, Inc. have a median 12-month price target of $20, with estimates ranging from $19 to $22. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is RCEL stock a buy right now?
Of the 3 analysts covering AVITA Medical, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks AVITA Medical, Inc. 85 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank RCEL?
As at 21 Nov 2026, AVITA Medical, Inc. ranks 85 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Momentum (98 of 100).
Will RCEL stock go up?
No one can know that. What the data says: the median 12-month target from 3 analysts implies +29.4% from the last close, and Ticker Nerd's factor model ranks AVITA Medical, Inc. 85 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the RCEL stock forecast for 2030?
No analyst covering AVITA Medical, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RCEL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $19 to $22 over the next 12 months.
How has RCEL stock performed over the past year?
AVITA Medical, Inc. returned +306.8% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does AVITA Medical, Inc. do?
AVITA Medical, Inc. is a therapeutic acute wound care company focused on regenerative solutions for skin restoration and wound healing. Its flagship RECELL System uses a patient’s own skin cells to create a spray-on cell suspension at the point of care for the treatment of thermal burn wounds, full-thickness skin defects, and stable depigmented vitiligo lesions.
About AVITA Medical, Inc.
AVITA Medical, Inc. is a therapeutic acute wound care company focused on regenerative solutions for skin restoration and wound healing. Its flagship RECELL System uses a patient’s own skin cells to create a spray-on cell suspension at the point of care for the treatment of thermal burn wounds, full-thickness skin defects, and stable depigmented vitiligo lesions. The company also markets PermeaDerm, a biosynthetic wound matrix, and Cohealyx, a collagen-based dermal matrix, supporting surgeons and clinicians in burn care, trauma care, and reconstructive procedures. AVITA Medical serves hospitals, treatment centers, and distributors across the United States, Japan, the European Union, Australia, and the United Kingdom. Headquartered in Valencia, California, AVITA Medical specializes in technologies designed to improve wound coverage and support clinical recovery in acute care settings.
CEO Mr. Cary G. Vance · 226 employees · United States · https://avitamedical.com